Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D-based CAR T-cells for Relapsed/Refractory NKG2DL+ Solid Tumors
NCT05131763Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR T cells in solid tumor, hepatocellular carcinoma (HCC), glioblastoma (GBM) and 2 more, sponsored by Fudan University. Primary endpoints: Treatment-related adverse events at 3 months and Adverse events at 3 months. Status: unknown.
02
Drugs
NKG2D CAR T cells
03
Conditions
solid tumorhepatocellular carcinoma (HCC)glioblastoma (GBM)medulloblastomacolon cancer
Beyond the preview
Go deeper on NCT05131763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131763.